Member Info for Dogs80

CC said at the interims , we will be speaking again in a few weeks time. That’s on Tuesday

I’m sure this happened last time too, they are not going to release all the new data in an abstract a week before the event starts. New data is coming next week I’m sure of it

Dual payload precision medicine is what is next Steve 😁

Who could it be

Go on CC , sounds so confident

They need some kind of funding but it doesn’t mean its going to be dilutive and even if it is, so long as avacta can get funded, what they have in the pipeline line will make any dilution a drop in the ocean, providing data is good, which it is expected to be.

Hi. I went to science day and also the agm.

From speaking and listening to Cc in person, there is so much we don’t know that is going on behind the scenes. We need to trust what she and the avacta team are doing.

Cc is incredible. We are so lucky to have her as CEO.

I personally am so confident in this company. Especially now RH is involved.

Cc was asked this question at end of the agm over coffee

She said they were expecting this question. Basically non of the directors believe they are in a position to be able to buy, given what they know. I don’t know the aim rules but maybe the under water part of the iceberg is preventing them from purchasing any shares

Haven’t they prioritised sgc instead of sts. Mainly because of the great sgc data but also because of other sts, pfs data that came out at a conference, which was very good and made sts more difficult for avacta to go after. Cc mentioned it at the agm

Also if you look at latest deck it says we are due a 6k update this month

I have to say, the quote at the head of CC twitter page is very encouraging too. Is that new? Don’t remember seeing it before.

Where does this come into it then

In October 2023, SOFIE and GE Healthcare (GEHC) entered a licensing agreement to develop, manufacture and commercialize [68Ga]FAPI-46 and [18F]FAPI-74 for diagnostic and companion diagnostic use. In this agreement, GE HealthCare will take on global rights for [68Ga]FAPI-46 and outside-US rights for [18F]FAPI-74. SOFIE will maintain clinical development and commercialization rights for [18F]FAPI-74 in the US.

The lft they were trying to rush out, precision they have been working on for years

Thanks JT i missed that. Was just trying to work out what could of been the hold up

I was thinking, the fact the third patient has only just been dosed in the bi weekly in US , could it be that they were only dosing one patient each month from beginning of the year?

This is great news we have also opened sites in the uk for the two week arm too.

My thoughts exactly

Bella is on form

Surely worth an rns